Population-based meta-analysis of hydrochlorothiazide pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 9, 2013, Pages 527-539

  Van Wart, Scott A ^a,b   Shoaf, Susan E ^c   Mallikaarjun, Suresh ^c   Mager, Donald E ^b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

heart failure; hydrochlorothiazide; population pharmacokinetics

Indexed keywords

HYDROCHLOROTHIAZIDE;

ARTICLE; COMPARTMENT MODEL; CONGENITAL HEART DISEASE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; OPEN STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY EXCRETION;

HEART FAILURE; HYDROCHLOROTHIAZIDE; POPULATION PHARMACOKINETICS;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; DIURETICS; HEART FAILURE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 84890562775     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1863     Document Type: Article

References (45)

1. Seely JF, Dirks JH,. Site of action of diuretic drugs. Kidney Int 1977; 11: 1-8.
2. Brater CD,. Pharmacology of diuretics. Am J Med Sci 2000; 319: 38-59.
3. Welling PG,. Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos 1986; 7: 501-535.
4. Beermann B, Groschinsky-Grind M, Rosén A,. Absorption, metabolism and excretion of [14C]-hydrochlorothiazide. Clin Pharmacol Ther 1976; 19: 531-537.
5. Meyer MC, Melikian AP, Whyatt PL, Slywka GW,. Hydrochlorothiazide bioavailability: an evaluation of thirteen products. Curr Ther Res Clin Exp 1975; 17: 570-577.
6. Beermann B, Groschinsky-Grind M,. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol 1979; 7: 579-583.
7. Hasannejad H, Takeda M, Taki K, et al,. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 2004; 308: 1021-1029.
8. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA,. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007; 50 (2): 213-222.
9. Jordö L, Johnsson G, Lundborg P, Persson B, Regärdh CG, Rönn O,. Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. Br J Clin Pharmacol 1979; 7: 563-567.
10. Vervaet C, Remon J,. Bioavailability of hydrochlorothiazide from pellets, made by extrusion/spheronisation, containing polyethylene glycol 400 as a dissolution enhancer. Pharm Res 1997; 14: 1644-1646.
11. Uderman HD, Much DR, Brennan J, et al,. Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction. Research reports. Ann Pharmacother 1999; 33: 525-530.
12. Yong CL, Dias VC, Stangier J,. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000; 40: 1323-1330.
13. Ndindayino F, Vervaet C, Van den Mooter G, Remon JP,. Bioavailability of hydrochlorothiazide from isomalt-based moulded tablets. Int J Pharm 2002; 246: 199-202.
14. Schürer M, Erb K, Junge K, et al,. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide: a clinical study to compare the pharmacokinetics after administration of spirapril combination bi-layer tablets. Blood 2003; 419: 414-420.
15. Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS,. Effect of the combination of lisinopril and hydrochlorothiazide on the bioequivalence of tablet formulations. Arzneimittelforschung 2004; 54: 605-610.
16. Niopas I, Daftsios AC, Nikolaidis N,. Evaluation of the bioequivalence of two tablet formulations of enalapril/hydrochlorothiazide after single oral administration to healthy volunteers. Arzneimittelforschung 2004; 54: 160-165.
17. Vaidyanathan S, Valencia J, Kemp C, et al,. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Practice 2006; 60: 1343-1356.
18. Kreutz R, Bolbrinker J, Huber M,. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Invest 2006; 26: 29-34.
19. Huang T, He Z, Yang B, Shao L, Zheng X, Duan G,. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution. J Pharm Biomed Anal 2006; 41: 644-648.
20. Yan T, Li H, Deng L, et al,. Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. J Pharm Biomed Anal 2008; 48: 1225-1229. doi: 10.1016/j.jpba.2008.08.021.
21. Parekh SA, Pudage A, Joshi SS, Vaidya VV, Gomes NA, Kamat SS,. Simultaneous determination of hydrochlorothiazide, quinapril and quinaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2008; 873: 59-69. doi: 10.1016/j.jchromb.2008.07.046.
22. Neves R, Almeida S, Filipe A, et al,. Bioequivalence study of two different film-coated tablet formulations of losartan-hydrochlorothiazide in healthy volunteers. Arzneimittelforschung 2008; 58: 369-375. doi: 10.1055/s-0031-1296523.
23. Tutunji MF, Ibrahim HM, Khabbas MH, Tutunji LF,. Simultaneous determination of bisoprolol and hydrochlorothiazide in human plasma by HPLC coupled with tandem mass spectrometry. J Chromatogr B 2009; 877: 1689-1697. doi: 10.1016/j.jchromb.2009.04.021.
24. Salvadori MC, Moreira RF, Borges BC, et al,. Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. Clin Exp Hyperten 2009; 31 (5): 415-427.
25. Gao F, Zhang M, Cui X, Wang Z, Sun Y, Gu J,. Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2010; 52: 149-154. doi: 10.1016/j.jpba.2009.12.012.
26. Patel A, Shah T, Shah G, et al,. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs 2010; 10: 95-103. doi: 10.2165/11532170-000000000-00000.
27. Tutunji LF, Tutunji MF, Alzoubi MI, Khabbas MH, Arida AI,. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: application to bioequivalence studies. J Pharm Biomed Anal 2010; 51: 985-990. doi: 10.1016/j.jpba.2009.10.023.
28. Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS,. Combination of losartan and hydrochlorothiazide: in vivo bioequivalence. Arzneimittelforschung 2004; 54: 611-617.
29. Giudicelli JF, Richer C, Mattei A,. Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. Br J Clin Pharmacol 1987; 23 (Suppl 1): 51S-63S.
30. Karara AH, Hanes V, Alonso A, et al,. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. J Clin Pharmacol 2007; 47: 1292-1302.
31. Fliser D, Bischoff I, Hanses A, et al,. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 1999; 55: 205-211.
32. Dickson TZ,. Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. J Clin Pharmacol 2003; 43: 591-603.
33. O'Grady P, Yee KF, Lins R, Mangold B,. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1999; 48: 375-381.
34. Piotrovskii VK,. The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharm Biopharm 1987; 15: 681-686.
35. Petricoul O, Cosson V, Fuseau E, Marchand M,. Population models for drug absorption and enterohepatic recycling. In Pharmacometrics: The Science of Quantitative Pharmacology, Ette EI, Williams PJ, (eds). John Wiley & Sons: Hoboken (NJ), 2007; 345-382.
36. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
37. Beal SL,. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
38. Ahn JE, Karlsson MO, Dunne A, Ludden TM,. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401-421. doi: 10.1007/s10928-008-9094-4.
39. Bergstrand M, Karlsson MO,. Handling data below the limit of quantification in mixed effect models. AAPS J 2009; 11: 371-380. doi: 10.1208/s12248-009-9112-5.
40. Ahn JE, French JL,. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 2010; 37: 179-201.
41. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13 (2): 143-151. doi: 10.1208/s12248-011-9255-z.
42. Greenland S,. Divergent biases in ecologic and individual-level studies. Stat Med 1992; 11: 1209-1223.
43. Greenland S, Morgenstern H,. Ecological bias, confounding, and effect modification. Int J Epidemiol 1989; 18: 269-274.
44. Blakely TA, Woodward AJ,. Ecological effects in multi-level studies. J Epidemiol Community Health 2000; 54: 367-374.
45. Sutton AJ, Kendrick D, Coupland CAC,. Meta-analysis of individual and aggregate-level data. Stat Med 2008; 27: 651-669.